Impact of genetic polymorphisms on platelet function and aspirin resistance

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 1, 2010, Pages 53-56

  Pamukcu, Burak ^a   Oflaz, Huseyin ^a   Onur, Imran ^a   Hancer, Veysel ^a   Yavuz, Selim ^a   Nisanci, Yilmaz ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Aspirin resistance; Coronary heart disease; Genetic polymorphisms

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; GLYCOPROTEIN IIIA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CHEMOSENSITIVITY; DNA HYBRIDIZATION; DNA ISOLATION; FEMALE; GENE AMPLIFICATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; AGED; ASPIRIN; BLOOD PROTEINS; COLLAGEN; DRUG RESISTANCE; EPINEPHRINE; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, GENETIC; THROMBOPHILIA;

EID: 75649105085     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328332ef66     Document Type: Article

References (23)

1. Murray CJ, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, Mass: Harvard University; 1996.
2. Rodgers A, Vaughan P. World Health Report 2002: reducing risks, promoting healthy life. Geneva, Switzerland: World Health Organization; 2002.
3. Ridker PM, Manson JE, Buring JE, Goldhaber SZ, Hennekens CH. The effect of chronic platelet inhibition with low dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from Physicians Health Study. Am Heart J 1991; 122:1588-1592.
4. 'Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106.
5. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88:230-235.
6. Pamukcu B. A review of aspirin resistance; definition, possible mechanisms,detection with platelet function tests, and its clinical outcomes. J Thromb Thrombolysis 2007; 23:213-222.
7. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet (erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression and gene chromosomal assignment. Fed Am Soc Exp Biol J 1991; 5:2304-2312.
8. Guo Q, Kulmacz RJ. Distinct influences of carboxyl terminal segment structure on function in the new isoforms of prostaglandin H synthase. Arch Biochem Biophys 2000; 384:269-279.
9. Ren Y, Loose-Mitchell DS, Kulmacz RJ. Prostaglandin H synthase-1: evaluation of c-terminus function. Arc Biochem Biophys 1995; 316:751-757.
10. Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T Kozak (GP Iba) polymorphisms. J Am Coll Cardiol 2003; 42:1115-1119.
11. Jefferson BK, Foster JH, McCarthy JJ, Ginsburg G, Parker A, Kottke- Marchant K, Topol EJ. Aspirin resistance and a single gene. Am J Cardiol 2005; 95:805-808.
12. Pamukcu B, Oflaz H, Onur I, Oncul A, Umman B, Koylan N, et al. Aspirinresistant platelet aggregation in a cohort of patients with coronary heart disease. Blood Coagul Fibrinolysis 2007; 18:461-465.
13. Mammen EF, Alsbameeri RS, Comp PC. Preliminary data from a field trial of the PFA-1001 system. Semin Thromb Hemost 1995; 21 (suppl.2):113-121.
14. Bö ck M, De Haan J, Beck KH, Gutensohn K, Hertfelder HJ, Karger R, et al. Standardization of the PFA-100(R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives. Br J Haematol 1999; 106:898-904.
15. Mahfouz RA, Sabbagh AS, Shammaa DM, Otrock ZK, Zaatari GS, Taher AT. Factor XIII gene V34L mutation in the Lebanese population: another unique feature in this community? Mol Biol Rep 2008; 35:375-378.
16. Kuijpers MJ, Munnix IC, Cosemans JM, Vlijmen BV, Reutelingsperger CP, Egbrink MO, Heemskerk JW. Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition. Microcirculation 2008; 15:269-282.
17. Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79:8-13.
18. Theodoropoulos I, Christopoulos C, Metcalfe P, Dimitriadou E, Economopoulos P, Loucopoulos D. The effect of human platelet alloantigen polymorphisms on the in vitro responsiveness to adrenaline and collagen. Br J Haematol 2001; 114:387-393.
19. Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O'Brien J, et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 10:2340-2345.
20. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101:1013-1018.
21. Pamukcu B, Oflaz H, Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J 2005; 149:675-680.
22. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008; 66: 222-232.
23. Kunicki TJ, Williams SA, Nugent DJ, Harrison P, Segal HC, Syed A, Rothwell PM. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost 2009; 101:123-133.